Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Vivos Therapeutics (VVOS) Preferred Shares Repurchased (2020)

Vivos Therapeutics has reported Preferred Shares Repurchased over the past 1 years, most recently at $2.0 million for Q4 2020.

Quarterly Preferred Shares Repurchased changed N/A to $2.0 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2021, down 6.98% year-over-year, with the annual reading at $1.5 million for FY2021, 30.23% down from the prior year.
Preferred Shares Repurchased was $2.0 million for Q4 2020 at Vivos Therapeutics, up from $150000.0 in the prior quarter.
Over five years, Preferred Shares Repurchased peaked at $2.0 million in Q4 2020 and troughed at $150000.0 in Q1 2020.